BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16005602)

  • 21. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?
    Leunen K; Drijkoningen M; Neven P; Christiaens MR; Van Ongeval C; Legius E; Amant F; Berteloot P; Vergote I
    Breast Cancer Res Treat; 2008 Jan; 107(1):79-86. PubMed ID: 17431765
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Foulkes WD; Kim-Sing C; Ainsworth P; Rosen B; Armel S; Poll A; Eisen A; Gilchrist D; Chudley A; Ghadirian P; Maugard C; Lemire EG; Sun P; Narod SA
    Clin Genet; 2008 May; 73(5):474-9. PubMed ID: 18341607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations.
    Schmeler KM; Sun CC; Bodurka DC; White KG; Soliman PT; Uyei AR; Erlichman JL; Arun BK; Daniels MS; Rimes SA; Peterson SK; Slomovitz BM; Milam MR; Gershenson DM; Lu KH
    Obstet Gynecol; 2006 Sep; 108(3 Pt 1):515-20. PubMed ID: 16946209
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer risks for Australian women with a BRCA1 or a BRCA2 mutation.
    Suthers GK
    ANZ J Surg; 2007 May; 77(5):314-9. PubMed ID: 17497966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prophylactic bilateral mastectomy: patterns of practice.
    Metcalfe KA; Goel V; Lickley L; Semple J; Narod SA
    Cancer; 2002 Jul; 95(2):236-42. PubMed ID: 12124821
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical characteristics affect the impact of an uninformative DNA test result: the course of worry and distress experienced by women who apply for genetic testing for breast cancer.
    van Dijk S; Timmermans DR; Meijers-Heijboer H; Tibben A; van Asperen CJ; Otten W
    J Clin Oncol; 2006 Aug; 24(22):3672-7. PubMed ID: 16877736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The twilight zone between health and sickness: a qualitative exploration with asymptomatic BRCA1 and 2 mutation carriers.
    Dagan E; Goldblatt H
    Women Health; 2009 Jun; 49(4):263-79. PubMed ID: 19753503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population-based study of changing breast cancer risk in Icelandic BRCA2 mutation carriers, 1920-2000.
    Tryggvadottir L; Sigvaldason H; Olafsdottir GH; Jonasson JG; Jonsson T; Tulinius H; Eyfjörd JE
    J Natl Cancer Inst; 2006 Jan; 98(2):116-22. PubMed ID: 16418514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
    Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stage of breast cancers found during the surveillance of women with a familial or hereditary risk.
    Kaas R; Muller SH; Hart AA; Rutgers EJ
    Eur J Surg Oncol; 2008 May; 34(5):501-7. PubMed ID: 17555911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hereditary breast-ovarian cancer: clinical findings and medical management.
    Marshall M; Solomon S
    Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. No evidence of false reassurance among women with an inconclusive BRCA1/2 genetic test result.
    Dorval M; Gauthier G; Maunsell E; Dugas MJ; Rouleau I; Chiquette J; Plante M; Laframboise R; Gaudet M; Bridge PJ; Simard J
    Cancer Epidemiol Biomarkers Prev; 2005 Dec; 14(12):2862-7. PubMed ID: 16365001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Cancer doesn't have an age': genetic testing and cancer risk management in BRCA1/2 mutation-positive women aged 18-24.
    Werner-Lin A; Hoskins LM; Doyle MH; Greene MH
    Health (London); 2012 Nov; 16(6):636-54. PubMed ID: 22547552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
    Hoskins KF; Zwaagstra A; Ranz M
    Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-reducing mastectomy in BRCA1/2 mutation carriers: factors influencing uptake and timing.
    van Driel CM; Eltahir Y; de Vries J; Jaspers JP; Oosterwijk JC; Mourits MJ; de Bock GH
    Maturitas; 2014 Feb; 77(2):180-4. PubMed ID: 24268650
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Newly diagnosed breast cancer patients choose bilateral mastectomy over breast-conserving surgery when testing positive for a BRCA1/2 mutation.
    Stolier AJ; Corsetti RL
    Am Surg; 2005 Dec; 71(12):1031-3. PubMed ID: 16447474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.